ArticlePloS one2025
Progression of keratoconus in the contralateral eye following acute corneal hydrops: A retrospective study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Keratoconus is a progressive eye disease characterised by thinning and bulging of the cornea, leading to distorted vision. Acute corneal hydrops, a rare and severe complication of keratoconus, occurs when fluid accumulates in the cornea due to a sudden break in its innermost layer, often causing pain, significant visual impairment, and sometimes requiring corneal transplantation. To better understand the risk of disease progression in the contralateral (unaffected) eye, we conducted a retrospective study at two major tertiary hospitals in Auckland, New Zealand. The study included 45 eyes from 45 patients presenting with acute corneal hydrops. Inclusion and exclusion criteria were rigorously applied to ensure that only patients eligible for corneal collagen crosslinking (CXL) at baseline were included, enhancing the clinical relevance of the findings. Patients were followed for a mean duration of 4.73 years. The results showed that 67% of contralateral eyes exhibited progression in at least one tomographic parameter, with 53.3% demonstrating progression in both anterior curvature and corneal thickness parameters. Higher baseline anterior curvature values and male sex were significantly associated with an increased risk of progression (p = 0.022 and p = 0.046, respectively). Nearly half of the eyes with progression had a thinnest corneal thickness of ≥400μm, making them eligible for CXL at initial presentation. However, 36% of these eligible eyes dropped below this threshold over the follow-up period, underscoring the importance of timely intervention to preserve treatment options. These findings highlight the importance of regular monitoring of the contralateral eye following acute corneal hydrops, particularly in male patients or those with advanced baseline disease. Immediate CXL may be considered in select cases to prevent disease progression. This study also emphasises the need for early intervention strategies and targeted healthcare services for populations at higher risk, including Māori and Pacific Peoples in Aotearoa-New Zealand, who experience disproportionately high burdens of keratoconus and health inequities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.